HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals With Buy Rating, Announces Price Target of $6
HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals With Buy Rating, Announces Price Target of $6
HC Wainwright & Co.以買入評級開始對Anebulo Pharmicals進行報道,宣佈目標股價爲6美元
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and announces Price Target of $6.
HC Wainwright&Co.分析師Raghuram Selvaraju以買入評級啟動對AneBulo製藥(納斯達克:ANEB)的報道,並宣佈目標價為6美元。